FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

By
Kathryn Wighton
April 29, 2026
4 min

Conexiant

Objective:

To highlight the significance of upcoming FDA regulatory decisions in various medical specialties for May 2026.

Approach:

Key Findings:

VYVGART shows efficacy in generalized myasthenia gravis regardless of antibody status, potentially changing treatment protocols.
LEQEMBI demonstrates long-term treatment persistence in clinical practice, indicating its viability as a long-term therapy.
Afrezza could become the first needle-free insulin for children in over a century, revolutionizing pediatric diabetes care.
CTx-1301 shows rapid and sustained symptom relief in ADHD patients, which could improve quality of life.

Interpretation:

The upcoming FDA decisions could significantly impact treatment options across multiple specialties, particularly for pediatric diabetes and ADHD, potentially leading to improved patient outcomes.

Limitations:

Pending FDA approvals may not guarantee market availability, and post-approval market dynamics could affect accessibility.
Real-world data may vary from clinical trial results, impacting the perceived efficacy and safety of these treatments.

Conclusion:

May 2026 is poised to be a pivotal month for FDA decisions that could enhance treatment options in neurology, endocrinology, psychiatry, and ophthalmology, underscoring the FDA's critical role in advancing healthcare.